Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

Liu, Qianyun; Xiong, Qing; Mei, Fanghua; Ma, Chengbao; Zhang, Zhen; Hu, Bing; Xu, Jin; Jiang, Yongzhong; Zhan, Faxian; Zhou, Sanming; Tao, Liyuan; Chen, Xianying; Guo, Ming; Wang, Xin; Fang, Yaohui; Shěn, Shū; Liu, Yingle; Liu, Fang; Zhou, Li; Xu, Ke; Ke, Changwen; Deng, Fei; Cai, Kun; Yan, Huan; Lan, Ke

doi:10.1016/j.xinn.2021.100181

Cited by 10 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, the fluorescent QD-peptides biosensors could also achieve over 92% sensitivity (vs. 78% sensitivity for ELISA) in authentic COVID-19 serum samples at 1:2000 serum dilution and avoid cross-reactions as much as possible by using SARS-CoV-2 specific B-cells epitopes. Our results are similar to the study by Liu et al (using overlapping sera) finding that high levels of specific antibodies were present 1 year after SARS-CoV-2 infection [ 27 ]. Still, our QD-peptides biosensors (98.1% sensitivity for QD-S epi1 at 1:2000 sera dilution) are more sensitive to the ELISA assay (RBD-based) at an even lower sera dilution (1:100) used in the study by Liu et al [ 27 ].…”

Section: Discussionsupporting

confidence: 92%

“…Our results are similar to the study by Liu et al (using overlapping sera) finding that high levels of specific antibodies were present 1 year after SARS-CoV-2 infection [ 27 ]. Still, our QD-peptides biosensors (98.1% sensitivity for QD-S epi1 at 1:2000 sera dilution) are more sensitive to the ELISA assay (RBD-based) at an even lower sera dilution (1:100) used in the study by Liu et al [ 27 ]. Thus, these comparisons once again prove the high sensitivity and advantage of saving sera material of our technology.…”

Section: Discussionsupporting

confidence: 92%

“…To validate the clinical sensitivity of the fluorescent QD-peptides biosensor, we tested 207 COVID-19 convalescents serum samples (infected by Wuhan strain) with different illness severity and 32 uninfected individuals’ serum samples [ 27 ] at 1:2000 serum dilutions. The results showed that the QD-peptides biosensors achieved higher sensitivity than protein-based ELISA assays.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection

Song

Cai

Liu

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

A new antibody diagnostic assay with more rapid and robust properties is demanded to quantitatively evaluate anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity in a large population. Here, we developed a nanometer-scale fluorescent biosensor system consisting of CdSe-ZnS quantum dots (QDs) coupled with the highly sensitive B-cell epitopes of SARS-CoV-2 that could remarkably identify the corresponding antibody with a detection limit of 100 pM. Intriguingly, we found that fluorescence quenching of QDs was stimulated more obviously when coupled with peptides than the corresponding proteins, indicating that the energy transfer between QDs and peptides was more effective. Compared to the traditional enzyme-linked immunosorbent assay (ELISA), the B-cell-epitope-based QD-biosensor could robustly distinguish coronavirus disease 2019 (COVID-19) antibody-positive patients from uninfected individuals with a higher sensitivity (92.3–98.1% positive rates by QD-biosensor vs. 78.3–83.1% positive rates by ELISAs in 207 COVID-19 patients’ sera) in a more rapid (5 min) and labor-saving manner. Taken together, the ‘QD-peptides’ biosensor provided a novel real-time, quantitative, and high-throughput method for clinical diagnosis and home-use tests.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection

Song

Cai

Liu

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data would have been useful to evaluate the extent and duration of the immune response against SARS-CoV-2. However, the anti-SARS-CoV-2 humoral immunity seems to last for at least 1 year in most convalescents, protecting them from the original virus, as reported by Liu et al [50]. Considering that most subjects were from Modena province, the reliability of seroprevalence estimates stratified by province may be low, especially considering the small sample size.…”

Section: Discussionmentioning

confidence: 91%

Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy

Paduano

Galante

Berselli

et al. 2022

IJERPH

View full text Add to dashboard Cite

Italy was the first Western European country to be severely hit by the COVID-19 pandemic. Variations in seroprevalence rates were reported according to geographical and temporal differences of previous surveys, as well as depending on demographic and occupational factors. In this cross-sectional study, we evaluated the prevalence of anti-SARS-CoV-2 antibodies in a population of the Emilia-Romagna region in Northern Italy after the first wave in the period from 26 September 2020–26 March 2021. We included 5128 subjects who voluntarily underwent serological tests to determine anti-SARS-CoV-2 antibody positivity, including both self-referred individuals (24.2%) and workers adhering to company screening programs (76.8%). Overall, seroprevalence was 11.3%, higher in self-referred (13.8%) than employed-referred (10.5%) individuals. A slightly higher seroprevalence emerged in women compared to men (12.3% and 10.7%), as well as in the extreme age categories (18.6% for 60–69 years, 18.0% for ≥70 years, and 17.1% for <20 years compared to 7.6% for 20–39 years). Healthcare professionals showed the highest prevalence of seropositivity (22.9%), followed by workers in direct contact with customers, such as the communication, finance, and tourism sectors (15.7%). Overall subgroups seroprevalence increased compared to the first wave data but the trends agreed between the first and subsequent waves, except for an increase in the younger age group and in the sector in direct contact with customers. Among the occupational categories, our study confirms that healthcare workers and workers in the sports sector were at high risk of exposure to SARS-CoV-2.

show abstract

“…Currently, a greatly increasing concern is the emergence of numerous SARS-CoV-2 variants resulting from the rapid spread and constant evolution of virus. In contrast to the potent neutralization against the WT SARS-CoV-2, varying degrees of immune escape by various variants, such as Beta (B.1.351), Delta (B.1.617.2), and Mu (B.1.621), have been observed in recovered human sera after one year [ 8 , 25 ]. In particular, with the emergence of various Omicron variants (BA.1, BA.2, and BA.4/5, etc.…”

Section: Discussionmentioning

confidence: 99%

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination

Wang

Zhou

Fan

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

With the ongoing COVID-19 pandemic and the emergence of various SARS-CoV-2 variants, a comprehensive evaluation of long-term efficacy of antibody response in convalescent individuals is urgently needed. Several longitudinal studies had reported the antibody dynamics after SARS-CoV-2 acute infection, but the follow-up was mostly limited to 1 year or 18 months at the maximum. In this study, we investigated the durability, potency, and susceptibility to immune evasion of SARS-CoV-2-specific antibody in COVID-19 convalescents for 2 years after discharge. These results showed the persistent antibody-dependent immunity could protect against the WT and Delta variant to some extent. However, the Omicron variants (BA.1, BA.2, and BA.4/5) largely escaped this preexisting immunity in recovered individuals. Furthermore, we revealed that inactivated vaccines (BBIBP-CorV, CoronaVac, or KCONVAC) could improve the plasma neutralization and help to maintain the broadly neutralizing antibodies at a certain level. Notably, with the time-dependent decline of antibody, 1-dose or 2-dose vaccination strategy seemed not to be enough to provide immune protection against the emerging variants. Overall, these results facilitated our understanding of SARS-CoV-2-induced antibody memory, contributing to the development of immunization strategy against SARS-CoV-2 variants for such a large number of COVID-19 survivors.

show abstract

Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

Cited by 10 publications

References 34 publications

B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection

B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection

Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination

Contact Info

Product

Resources

About